HiQCell

**HiQCell** is an autologous cell therapy developed by Regeneus Ltd, utilizing adipose-derived mesenchymal stem cells (MSCs) extracted from a patient's own fat tissue, processed in-clinic, and injected into affected joints or tendons. It aims to reduce inflammation, alleviate pain, halt cartilage degradation, and repair damaged tissue in osteoarthritis (OA) patients, with demonstrated safety in over 1,000 treated joints and efficacy in reducing pain (73% at 1 year, 82% at 2 years), improving joint function, sleep quality, and reducing medication reliance per registry data and the double-blind OSCARS study. The therapy leverages the regenerative properties of MSCs without a specific defined molecular target, relying on paracrine effects for anti-inflammatory and tissue repair benefits.[2][3][5][7]

Brand names

HiQCell